logo
Share SHARE
FONT-SIZE Plus   Neg

General Mills Lowers FY17 Outlook - Quick Facts

Packaged food company General Mills (GIS) said that in response to revised second-half growth expectations driven largely by recent sales performance on U.S. yogurt and soup, the company is reducing its sales and earnings outlook for the fiscal year ending May 2017.

General Mills said its fiscal 2017 organic net sales are now expected to decline approximately 4 percent. This represents the low end of the previous range of a 3 to 4 percent decline, due primarily to a widening gap between the company's level of promotional activity and that of competitors in the U.S. yogurt and soup categories.

The company now forecasts fiscal 2017 adjusted earnings per share to increase 5 percent to 7 percent in constant currency, and adjusted operating profit margin of at least 18 percent, which represents an increase of at least 120 basis points over fiscal 2016 levels.

Previously, General Mills was targeting adjusted earnings per share growth of 6 percent to 8 percent in constant currency and 150 basis points of improvement in adjusted operating profit margin.

General Mills said it is committed to pursuing its Consumer First strategy and leveraging its five global platforms - cereal, snacks, yogurt, convenient meals, and super-premium ice cream - along with its new global organizational structure to achieve its goal of creating market-leading growth to deliver top-tier shareholder returns.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Best Buy announced Wednesday its plans to introduce Amazon Alexa and Google Home experiences to its 700 locations across the U.S. starting next month as part of its strategy of pushing smart home technology. A nationwide rollout will be complete by the end of the year. The electronics retailer will expand space at selected stores to better showcase how Amazon's Echo and Google Home interact.. So far this year, 23 novel drugs have already received FDA approval. Now let's take a look at the biotech stocks waiting to hear from the FDA in July. President Donald Trump has continued his assault on one of his favorite targets on Wednesday, lashing out at major media outlets in a series of posts on Twitter. Trump singled out the New York Times and the Washington Post in his tweets, describing the newspapers as "fake news."
comments powered by Disqus
Follow RTT